BioSpace News Archive

Affimed N.V. announced that its 2023 Annual General Meeting of Shareholders will be held on June 21, 2023 at 14:00 CET at the NH Collection Amsterdam Barbizon Palace, Prins Hendrikkade 59-72, 1012 AD Amsterdam, the Netherlands.

Viatris Inc. today announced that as part of its ongoing board refreshment efforts, Leo Groothuis has been appointed as Viatris’ newest member of its board of directors.

TransCode Therapeutics, Inc. today announced that its Board of Directors approved a 1-for-20 reverse stock split, to be effective 4:05 p.m. Eastern Time today, May 22, 2023.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Public Health Institute (ISP) of Chile has granted marketing authorization for oral, once-daily ORLADEYO ® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in patients 12 years of age or older.

Athira Pharma, Inc. today announced the appointment of Andrew Gengos as Chief Financial Officer and Chief Business Officer, effective immediately.

NeuBase Therapeutics, Inc. today announced a broad set of preclinical safety and efficiency data for its Stealth Editors development program that demonstrate the ability to achieve gene editing with a non-immunogenic system.

Endotronix, Inc. today announced positive 12-month data from the SIRONA 2 clinical trial that demonstrated long-term use of the Cordella Pulmonary Artery (PA) Sensor was associated with significant improvements in patient quality-of-life metrics and low HF hospitalization and death (HFH/D) event rates for New York Heart Failure (NYHA) class III patients.

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present in a fireside chat and panel as well as host one-on-one investor meetings at the Barclays Gene Editing & Therapy Summit 2023 on Wednesday, May 24, 2023.

Avantor, Inc. has entered into an agreement with Labguru, a research-to-production platform of choice for leading global pharma, national research institutes and innovative startups, to integrate Avantor’s Inventory Manager and e-commerce channel into Labguru’s Lab Information Management Software (LIMS) and Electronic Lab Notebook (ELN).

AVROBIO, Inc today announced an agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5 million in cash.